While there has been a slight improvement in the availability of platinum-based chemotherapy agents, most institutions are still facing shortages and “living paycheck to paycheck” with the drugs, a survey revealed.
Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.